Remdesivir is a carboxylic ester resulting from the formal condensation of the carboxy group of N- [ (S)- { [ (2R,3S,4R,5R)-5- (4-aminopyrrolo [2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy} (phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol.

ChemSpider record containing structure, synonyms, properties, vendors and database links for remdesivir, 1809249-37-3, RWWYLEGWBNMMLJ-YSOARWBDSA-N

(R)-Remdesivir | C27H35N6O8P | CID 76415573 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

Remdesivir (RDV, Veklury®) is a once-daily, nucleoside ribonucleic acid polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication.

Remdesivir is an investigational nucleotide analogue with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including...

Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity, is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by severe ...

Case report study of the first five COVID-19 patients treated with remdesivir in France. [Int J Infect Dis. 2020] Review Molnupiravir. [LiverTox: Clinical and Researc...] Review Remdesivir against COVID-19 and Other Viral Diseases. [Clin Microbiol Rev. 2020] Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.

Dec 27, 2020 · Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV), was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro.

Apr 9, 2020 · Here we report the cryo-electron microscopy structure of the SARS-CoV-2 RdRp, both in the apo form at 2.8-angstrom resolution and in complex with a 50-base template-primer RNA and remdesivir at 2.5-angstrom resolution.

Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis.